[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer.
Purpose: The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [89Zr]trastuzumab in patients with HER2-positive breast cancer.Procedures: Twelve women with HER2-positive breast cancer underwent [89Zr]trastuzumab positron emission tomography (P...
| Publicado en: | Molecular Imaging & Biology Vol. 18; no. 6; pp. 952 - 960 |
|---|---|
| Autores principales: | , , , , , , , , , , , |
| Formato: | clinical trial research Journal Article |
| Publicado: |
Springer Nature
Dec2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=119581279&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 119581279 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15361632 KJU jtl: Molecular Imaging & Biology issn: 15361632 maglogo: N pubinfo: dt: Dec2016 vid: 18 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 119581279 119581279 NLM27146421 119581279 10.1007/s11307-016-0951-z NLM27146421 119581279 ppf: 952 ppct: 8 formats: fmt: @attributes: type: P tig: atl: [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. aug: au: Laforest, Richard Lapi, Suzanne E Oyama, Reiko Bose, Ron Tabchy, Adel Marquez-Nostra, Bernadette V Burkemper, Jennifer Wright, Brian D Frye, Jennifer Frye, Sarah Siegel, Barry A Dehdashti, Farrokh affil: Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA sug: subj: Radioisotopes Metals Adult Receptors, Cell Surface Metabolism Aged Radiometry Breast Neoplasms Pathology Breast Neoplasms Time Factors Female Human Middle Age Clinical Trials Validation Studies Comparative Studies Evaluation Research Multicenter Studies Funding Source Adult: 19-44 years Aged: 65+ years Middle Aged: 45-64 years Female ab: Purpose: The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [89Zr]trastuzumab in patients with HER2-positive breast cancer.Procedures: Twelve women with HER2-positive breast cancer underwent [89Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were created using data from all patients. Human dosimetry was calculated using OLINDA with the adult female model.Results: High-quality images and the greatest tumor-to-nontumor contrast were achieved with images performed 5 ± 1 day post-injection. Increased [89Zr]trastuzumab uptake was seen in at least one known lesion in ten patients. The liver was the dose-limiting organ (retention of ∼12 % of the injected dose and average dose of 1.54 mSv/MBq). The effective dose was 0.47 mSv/MBq. No adverse effects of [89Zr]trastuzumab were encountered.Conclusion: [89Zr]trastuzumab was safe and optimally imaged at least 4 days post-injection. The liver was the dose-limiting organ. pubtype: Academic Journal doctype: clinical trial research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|